SGHTNMSHealthcare·Medical Devices#73 in industry

Sight Sciences, Inc.

Reports in 9d· 2026-05-06

-28.2% · 90d

$4.32

-0.04 (-0.92%)

After-Hours $4.32(+0.00)

News

(1)

April 2026

Apr 22, 20265 days agoDEF 14AHealthcare

Sight Sciences, Inc. — DEF 14A Filing

SGHTSight Sciences, Inc.

# 🧾 What This Document Is This is a **proxy statement** (Form DEF 14A) for Sight Sciences, Inc. Think of it as a detailed "voter's guide" for the company's shareholders. Its main purpose is to provide all the information shareholders need to vote on important company matters ahead of the 2026 Annu

Read summaryView on SEC EDGAR

Key Data

Market Cap$235.0M

Open$4.42

Prev Close$4.36

Day Range$4.28 – $4.46

52W Range$2.74 – $9.24

Volume146,353

P/E (TTM)—

EPS$-0.74

Dividend Yield—

Beta2.49

Profit Margin-49.67%

Revenue Growth6.90%

Price Target$8.34(+93.0%)

Next Earnings2026-05-06(9d)

Analyst Ratings

Strong Buy6 analysts

Buy 4Hold 2Sell 0

About

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.

Healthcare · Medical Devices

186 employees

www.sightsciences.com